AR057810A1 - Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica - Google Patents
Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceuticaInfo
- Publication number
- AR057810A1 AR057810A1 ARP060103981A ARP060103981A AR057810A1 AR 057810 A1 AR057810 A1 AR 057810A1 AR P060103981 A ARP060103981 A AR P060103981A AR P060103981 A ARP060103981 A AR P060103981A AR 057810 A1 AR057810 A1 AR 057810A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- alkoxy
- piperazinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los compuestos de la formula (1), sales farmacéuticamente aceptables del mismo y composiciones. Los compuestos tienen actividad contra el virus de hepatitis C (VHC) y son utiles en el tratamiento de aquellos infectados con VHC. Reivindicacion 1: Un compuesto de la formula (1), en donde: R1 es CO2R5 o CONR6R7; R2 es hidroxi, alcoxi C1-6, NR8R9, o R3 es hidrogeno, halo, alquilo C1-6, o alcoxi C1-6; R4 es cicloalquilo C5-7; R5 es hidrogeno o alquilo; R6 es hidrogeno, alquilo C1-6, cicloalquilo C3- 7, alcoxi C1-6, o SO2R10; R7 es hidrogeno, alquilo C1-6, o cicloalquilo C3-7; R8 es hidrogeno, alquilo C1-6, cicloalquilo C3-7, hidroxialquilo C1-6, alcoxiC1-6-alquiloC1-6, aminoalquilo C1-6, alquilaminoC1-6-alquiloC1-6, diquilaminoC1-6-alquilo C1- 6, R9 es hidrogeno, alquilo C1-6, cicloalquilo C3-7, hidroxialquilo C1-6, alcoxiC1-6-alquiloC1-6, aminoalquilo C1-6, alquilaminoC1-6-alquiloC1-6, dialquilaminoC1-6-alquiloC1-6; o NR8 R9 al tomarse junto es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es sustituid o con 0-2 sustituyentes seleccionados de halo, hidroxi, alquilo C1-6, amino, alquilamino C1-6, dialquilamino C1-6, pirrolidinilo, piperidinilo, piperazinilo, N- (alquiloC1-6)piperazinilo, morfolinilo y tiomorfolinilo; y R10 es alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7, amino, alquilamino C1-6, dialquilamino C1-6, o R10 es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es sustituido con 0-2 sustituyentes seleccionados de halo y alquilo c1-6; o una sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71618705P | 2005-09-12 | 2005-09-12 | |
US80997906P | 2006-06-01 | 2006-06-01 | |
US11/507,731 US7399758B2 (en) | 2005-09-12 | 2006-08-22 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057810A1 true AR057810A1 (es) | 2007-12-19 |
Family
ID=37603284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103981A AR057810A1 (es) | 2005-09-12 | 2006-09-12 | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica |
Country Status (5)
Country | Link |
---|---|
US (2) | US7399758B2 (es) |
AR (1) | AR057810A1 (es) |
PE (1) | PE20070676A1 (es) |
TW (1) | TW200745035A (es) |
WO (1) | WO2007033032A1 (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005049622A1 (ja) * | 2003-11-19 | 2007-06-07 | 日本たばこ産業株式会社 | 5−5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途 |
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7795247B2 (en) | 2004-10-26 | 2010-09-14 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
GB0608928D0 (en) * | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
ES2343914T3 (es) * | 2006-05-25 | 2010-08-12 | Bristol-Myers Squibb Company | Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo. |
US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
CN101679437B (zh) * | 2007-03-13 | 2013-04-17 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538103B2 (en) | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
AU2008277440A1 (en) * | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis C infections |
US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
CN101918410B (zh) * | 2007-11-20 | 2013-02-27 | 百时美施贵宝公司 | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
JP5623289B2 (ja) | 2007-12-19 | 2014-11-12 | ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
WO2009080836A2 (en) | 2007-12-24 | 2009-07-02 | Tibotec Pharmaceuticals Ltd. | Macrocyclic indoles as hepatitis c virus inhibitors |
MX2010008523A (es) * | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
AU2009228337A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2009120733A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
JP2011517673A (ja) | 2008-03-27 | 2011-06-16 | ブリストル−マイヤーズ スクイブ カンパニー | 芳香族ヘテロ環縮合インドロベンザジアゼピンhcvns5b阻害剤 |
US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
AU2010203656A1 (en) | 2009-01-07 | 2011-07-21 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of HCV and HIV infection |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス,インコーポレイテッド | ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤 |
WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US9127010B2 (en) | 2010-06-24 | 2015-09-08 | Janssen Sciences Ireland Uc | Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid |
EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
JP6306002B2 (ja) * | 2012-07-18 | 2018-04-04 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドBristol−Myers Squibb Holdings Ireland | (4bS,5aR)−12−シクロヘキシル−N−(N,N−ジメチルスルファモイル)−3−メトキシ−5a−((1R,5S)−3−メチル−3,8−ジアザビシクロ[3.2.1]オクタン−8−カルボニル)−4b,5,5a,6−テトラヒドロベンゾ[3,4]シクロプロパ[5,6]アゼピノ[1,2−A]インドール−9−カルボキサミドを製造するための新規な方法および中間体 |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1719773T3 (da) | 2004-02-24 | 2009-06-29 | Japan Tobacco Inc | Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7348425B2 (en) * | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
EP1799679B1 (de) | 2004-10-13 | 2008-01-23 | Merck Patent GmbH | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
BRPI0516972A (pt) | 2004-10-26 | 2008-09-30 | Angeletti P Ist Ricerche Bio | composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
-
2006
- 2006-08-22 US US11/507,731 patent/US7399758B2/en active Active
- 2006-09-11 WO PCT/US2006/035133 patent/WO2007033032A1/en active Application Filing
- 2006-09-12 TW TW095133730A patent/TW200745035A/zh unknown
- 2006-09-12 PE PE2006001104A patent/PE20070676A1/es not_active Application Discontinuation
- 2006-09-12 AR ARP060103981A patent/AR057810A1/es unknown
-
2007
- 2007-03-12 US US11/684,710 patent/US7485633B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20070184024A1 (en) | 2007-08-09 |
US7485633B2 (en) | 2009-02-03 |
PE20070676A1 (es) | 2007-08-10 |
WO2007033032A1 (en) | 2007-03-22 |
US20070060565A1 (en) | 2007-03-15 |
TW200745035A (en) | 2007-12-16 |
US7399758B2 (en) | 2008-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
AR055165A1 (es) | Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. | |
JP2010521483A5 (es) | ||
EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
DE602005023015D1 (de) | Indolderivate als viruzide | |
AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
DE602005022764D1 (de) | Piperidin- und azetidinderivate als glyt1-inhibitoren | |
TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
AR082619A1 (es) | Inhibidores del virus de la hepatitis c | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR049739A1 (es) | Derivados de aril-piridina | |
AR039566A1 (es) | Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion | |
AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
HUP0402679A2 (hu) | Pirrolidin- és piperidin-származékok mint NK1 antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
AR073586A1 (es) | Compuestos heterociclicos utiles para el tratamiento de vhc | |
ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |